유럽의 임상 바이오마커 시장 : 분석과 예측(2023-2033년)

Introduction to Europe Clinical Biomarkers Market

The Europe clinical biomarkers market was valued at $7.19 billion in 2023 and is expected to reach $14.84 billion by 2033, growing at a CAGR of 7.52% between 2023 and 2033. Clinical biomarkers are biological factors that can be measured to help in early diagnosis and understanding of the course of a disease. These molecular biomarkers provide new avenues for the study of diseases and the development of therapeutics. The producers of numerous biomarker-based tests, such as prognostic, predictive, and diagnostic biomarkers, as well as associated services, are highlighted in this research.

Market Introduction

The market for clinical biomarkers in Europe is expanding significantly, propelled by developments in biotechnology and molecular biology. Clinical biomarkers are biological factors that may be measured. They are essential for comprehending the course of disease, helping with early diagnosis, and discovering novel targets for treatment. Prognostic, predictive, and diagnostic biomarkers are only a few of the many biomarker-based tests available in this sector, along with associated services. Three major drivers are driving the industry forward: increased investments in research and development, growing desire for personalized treatment, and rising prevalence of chronic diseases. Furthermore, Europe's regulatory environment is changing to facilitate the creation and application of novel biomarker technologies. To meet the increasing demand, top manufacturers and service providers are concentrating on broadening their product offerings and improving their technological prowess. This report delves into the current market dynamics, key players, and future trends shaping the European clinical biomarkers market.

Market Segmentation

Segmentation 1: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments, at nearly 59% of the total developments in the clinical biomarkers market between January 2019 and December 2023. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The Europe clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are

• ALCEN
• bioMerieux S.A.
• CENTOGENE N.V.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• QIAGEN N.V.

Table of Contents

Executive Summary

1 Market

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion

2 Market Scope

• 2.1 Key Questions Answered in the Report

3 Research Methodology

• 3.1 Data Sources
  • 3.1.1 Primary Data Source
  • 3.1.2 Secondary Data Sources
    • 3.1.2.1 Open Sources
• 3.2 Market Estimation Model
• 3.3 Criteria for Company Profiling

4 Market Overview

• 4.1 Introduction
• 4.2 Clinical Biomarkers Approaches in Precision Medicine
• 4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
• 4.4 COVID-19 Impact on Clinical Biomarkers Market
  • 4.4.1 COVID-19 Impact on Market Size
• 4.5 Market Trends
  • 4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
  • 4.5.2 Increasing Biomarkers Usage in Precision Medicine
  • 4.5.3 Technologies Being Used in Clinical Biomarker Testing
  • 4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region

• 5.1 Overview
• 5.2 Europe
  • 5.2.1 Germany
  • 5.2.2 France
  • 5.2.3 U.K.
  • 5.2.4 Italy
  • 5.2.5 Spain
  • 5.2.6 Rest-of-Europe

6 Market - Company Profiles

• 6.1 Overview
• 6.2 ALCEN
  • 6.2.1 Company Overview
  • 6.2.2 Role of ALCEN in the Clinical Biomarkers Market
  • 6.2.3 Analyst's Perspective
• 6.3 bioMerieux S.A.
  • 6.3.1 Company Overview
  • 6.3.2 Role of bioMerieux S.A. in the Clinical Biomarkers Market
  • 6.3.3 Corporate Strategies
    • 6.3.3.1 Funding and Expansion
    • 6.3.3.2 Product Launches
  • 6.3.4 Financials
  • 6.3.5 Analyst's Perspective
• 6.4 CENTOGENE N.V.
  • 6.4.1 Company Overview
  • 6.4.2 Role of CENTOGENE N.V. in the Clinical Biomarkers Market
  • 6.4.3 Business Strategies
    • 6.4.3.1 Funding
  • 6.4.4 Corporate Strategies
    • 6.4.4.1 Synergistic Activities
  • 6.4.5 Financials
  • 6.4.6 Analyst's Perspective
• 6.5 Eurofins Scientific
  • 6.5.1 Company Overview
  • 6.5.2 Role of Eurofins Scientific in the Clinical Biomarkers Market
  • 6.5.1 Corporate Strategies
    • 6.5.1.1 Product Launches
  • 6.5.2 Financials
  • 6.5.3 Analyst's Perspective
• 6.6 F. Hoffmann-La Roche Ltd
  • 6.6.1 Company Overview
  • 6.6.2 Role of F. Hoffmann-La Roche Ltd in the Clinical Biomarkers Market
  • 6.6.3 Business Strategies
    • 6.6.3.1 Product Launches
  • 6.6.4 Corporate Strategies
    • 6.6.4.1 Synergistic Activities
  • 6.6.5 Financials
  • 6.6.6 Analyst's Perspective
• 6.7 QIAGEN N.V.
  • 6.7.1 Company Overview
  • 6.7.2 Role of QIAGEN N.V. in the Clinical Biomarkers Market
  • 6.7.3 Corporate Strategies
    • 6.7.3.1 Product Launches
  • 6.7.4 Business Strategies
    • 6.7.4.1 Synergistic Activities
  • 6.7.5 Financials
  • 6.7.6 Analyst's Perspective